APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nucleic Acids for Molecular Diagnosis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nucleic Acids for Molecular Diagnosis Market Outlook and Growth Opportunities 2026

25 December 2025197 pages

Choose your research edition.

Industry ResearchNucleic Acids for Molecular Diagnosis Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Nucleic Acids for Molecular Diagnosis Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Nucleic Acids for Molecular Diagnosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nucleic Acids for Molecular Diagnosis Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Nucleic Acids for Molecular Diagnosis Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Nucleic Acids for Molecular Diagnosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nucleic Acids for Molecular Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nucleic Acids for Molecular Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nucleic Acids for Molecular Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nucleic Acids for Molecular Diagnosis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nucleic Acids for Molecular Diagnosis market include Agilent Technologies, Inc., Aji Bio-Pharma, Bio-synthesis Inc., Danaher Corporation, Eurofins Scientific SE, Integrated DNA Technologies, Kaneka Eurogentec S.A., L.G.C Biosearch Technologies and Merck KGaA, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nucleic Acids for Molecular Diagnosis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nucleic Acids for Molecular Diagnosis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nucleic Acids for Molecular Diagnosis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nucleic Acids for Molecular Diagnosis market.

Nucleic Acids for Molecular Diagnosis Segment by Company

Agilent Technologies, Inc.

Aji Bio-Pharma

Bio-synthesis Inc.

Danaher Corporation

Eurofins Scientific SE

Integrated DNA Technologies

Kaneka Eurogentec S.A.

L.G.C Biosearch Technologies

Merck KGaA

metabion

QIAGEN

Thermo Fisher Scientific Inc.

Hongene

Synthgene

Nucleic Acids for Molecular Diagnosis Segment by Type

DNA Series

RNA Series

Nucleic Acids for Molecular Diagnosis Segment by Application

Early Cancer Screening

Genetic Diseases

Blood Screening

Genome Sequencing

Infectious Diseases

Other

Nucleic Acids for Molecular Diagnosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nucleic Acids for Molecular Diagnosis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nucleic Acids for Molecular Diagnosis key companies, revenue, market share, and recent developments.

3. To split the Nucleic Acids for Molecular Diagnosis breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nucleic Acids for Molecular Diagnosis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nucleic Acids for Molecular Diagnosis significant trends, drivers, influence factors in global and regions.

6. To analyze Nucleic Acids for Molecular Diagnosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Acids for Molecular Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nucleic Acids for Molecular Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Acids for Molecular Diagnosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nucleic Acids for Molecular Diagnosis industry.

Chapter 3: Detailed analysis of Nucleic Acids for Molecular Diagnosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nucleic Acids for Molecular Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nucleic Acids for Molecular Diagnosis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nucleic Acids for Molecular Diagnosis Industry Trends Table 2. Nucleic Acids for Molecular Diagnosis Industry Drivers Table 3. Nucleic Acids for Molecular Diagnosis Industry Opportunities and Challenges Table 4. Nucleic Acids for Molecular Diagnosis Industry Restraints Table 5. Global Nucleic Acids for Molecular Diagnosis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nucleic Acids for Molecular Diagnosis Revenue Share by Company (2021-2026) Table 7. Global Nucleic Acids for Molecular Diagnosis Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nucleic Acids for Molecular Diagnosis Key Company Manufacturing Base & Headquarters Table 9. Global Nucleic Acids for Molecular Diagnosis Company, Product Type & Application Table 10. Global Nucleic Acids for Molecular Diagnosis Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nucleic Acids for Molecular Diagnosis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DNA Series Table 15. Significant Companies of RNA Series Table 16. Global Nucleic Acids for Molecular Diagnosis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Nucleic Acids for Molecular Diagnosis Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Nucleic Acids for Molecular Diagnosis Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Type (2021-2026) Table 20. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Early Cancer Screening Table 22. Significant Companies of Genetic Diseases Table 23. Significant Companies of Blood Screening Table 24. Significant Companies of Genome Sequencing Table 25. Significant Companies of Infectious Diseases Table 26. Significant Companies of Other Table 27. Global Nucleic Acids for Molecular Diagnosis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nucleic Acids for Molecular Diagnosis Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nucleic Acids for Molecular Diagnosis Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Application (2021-2026) Table 31. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Application (2027-2032) Table 32. Global Nucleic Acids for Molecular Diagnosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nucleic Acids for Molecular Diagnosis Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Region (2021-2026) Table 35. Global Nucleic Acids for Molecular Diagnosis Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Region (2027-2032) Table 37. Global Nucleic Acids for Molecular Diagnosis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nucleic Acids for Molecular Diagnosis Sales Value Market Share by Country (2021-2026) Table 40. Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nucleic Acids for Molecular Diagnosis Sales Value Market Share by Country (2027-2032) Table 42. Agilent Technologies, Inc. Company Information Table 43. Agilent Technologies, Inc. Business Overview Table 44. Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio Table 46. Agilent Technologies, Inc. Recent Development Table 47. Aji Bio-Pharma Company Information Table 48. Aji Bio-Pharma Business Overview Table 49. Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Portfolio Table 51. Aji Bio-Pharma Recent Development Table 52. Bio-synthesis Inc. Company Information Table 53. Bio-synthesis Inc. Business Overview Table 54. Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio Table 56. Bio-synthesis Inc. Recent Development Table 57. Danaher Corporation Company Information Table 58. Danaher Corporation Business Overview Table 59. Danaher Corporation Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Portfolio Table 61. Danaher Corporation Recent Development Table 62. Eurofins Scientific SE Company Information Table 63. Eurofins Scientific SE Business Overview Table 64. Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Portfolio Table 66. Eurofins Scientific SE Recent Development Table 67. Integrated DNA Technologies Company Information Table 68. Integrated DNA Technologies Business Overview Table 69. Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio Table 71. Integrated DNA Technologies Recent Development Table 72. Kaneka Eurogentec S.A. Company Information Table 73. Kaneka Eurogentec S.A. Business Overview Table 74. Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Portfolio Table 76. Kaneka Eurogentec S.A. Recent Development Table 77. L.G.C Biosearch Technologies Company Information Table 78. L.G.C Biosearch Technologies Business Overview Table 79. L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio Table 81. L.G.C Biosearch Technologies Recent Development Table 82. Merck KGaA Company Information Table 83. Merck KGaA Business Overview Table 84. Merck KGaA Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Merck KGaA Nucleic Acids for Molecular Diagnosis Product Portfolio Table 86. Merck KGaA Recent Development Table 87. metabion Company Information Table 88. metabion Business Overview Table 89. metabion Nucleic Acids for Molecular Diagnosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. metabion Nucleic Acids for Molecular Diagnosis Product Portfolio Table 91. metabion Recent Development Table 92. QIAGEN Company Information Table 93. QIAGEN Business Overview Table 94. QIAGEN Nucleic Acids for Molecular Diagnosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. QIAGEN Nucleic Acids for Molecular Diagnosis Product Portfolio Table 96. QIAGEN Recent Development Table 97. Thermo Fisher Scientific Inc. Company Information Table 98. Thermo Fisher Scientific Inc. Business Overview Table 99. Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio Table 101. Thermo Fisher Scientific Inc. Recent Development Table 102. Hongene Company Information Table 103. Hongene Business Overview Table 104. Hongene Nucleic Acids for Molecular Diagnosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Hongene Nucleic Acids for Molecular Diagnosis Product Portfolio Table 106. Hongene Recent Development Table 107. Synthgene Company Information Table 108. Synthgene Business Overview Table 109. Synthgene Nucleic Acids for Molecular Diagnosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Synthgene Nucleic Acids for Molecular Diagnosis Product Portfolio Table 111. Synthgene Recent Development Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Nucleic Acids for Molecular Diagnosis Product Image Figure 2. Global Nucleic Acids for Molecular Diagnosis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nucleic Acids for Molecular Diagnosis Market Size (2021-2032) & (US$ Million) Figure 4. Global Nucleic Acids for Molecular Diagnosis Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DNA Series Image Figure 8. RNA Series Image Figure 9. Global Nucleic Acids for Molecular Diagnosis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Nucleic Acids for Molecular Diagnosis Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Type (2021-2032) Figure 12. Early Cancer Screening Image Figure 13. Genetic Diseases Image Figure 14. Blood Screening Image Figure 15. Genome Sequencing Image Figure 16. Infectious Diseases Image Figure 17. Other Image Figure 18. Global Nucleic Acids for Molecular Diagnosis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nucleic Acids for Molecular Diagnosis Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Application (2021-2032) Figure 21. Global Nucleic Acids for Molecular Diagnosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nucleic Acids for Molecular Diagnosis Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nucleic Acids for Molecular Diagnosis Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nucleic Acids for Molecular Diagnosis Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nucleic Acids for Molecular Diagnosis Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nucleic Acids for Molecular Diagnosis Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Series
  • RNA Series
Applications
  • Early Cancer Screening
  • Genetic Diseases
  • Blood Screening
  • Genome Sequencing
  • Infectious Diseases
  • Other
Companies covered
  • Agilent Technologies, Inc.
  • Aji Bio-Pharma
  • Bio-synthesis Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • Integrated DNA Technologies
  • Kaneka Eurogentec S.A.
  • L.G.C Biosearch Technologies
  • Merck KGaA
  • metabion
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Hongene
  • Synthgene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nucleic Acids for Molecular Diagnosis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nucleic Acids for Molecular Diagnosis Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nucleic Acids for Molecular Diagnosis Market Dynamics
  1. 2.1 Nucleic Acids for Molecular Diagnosis Industry Trends
  2. 2.2 Nucleic Acids for Molecular Diagnosis Industry Drivers
  3. 2.3 Nucleic Acids for Molecular Diagnosis Industry Opportunities and Challenges
  4. 2.4 Nucleic Acids for Molecular Diagnosis Industry Restraints
3 Nucleic Acids for Molecular Diagnosis Market by Company
  1. 3.1 Global Nucleic Acids for Molecular Diagnosis Company Revenue Ranking in 2025
  2. 3.2 Global Nucleic Acids for Molecular Diagnosis Revenue by Company (2021-2026)
  3. 3.3 Global Nucleic Acids for Molecular Diagnosis Company Ranking (2024-2026)
  4. 3.4 Global Nucleic Acids for Molecular Diagnosis Company Manufacturing Base and Headquarters
  5. 3.5 Global Nucleic Acids for Molecular Diagnosis Company Product Type and Application
  6. 3.6 Global Nucleic Acids for Molecular Diagnosis Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nucleic Acids for Molecular Diagnosis Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nucleic Acids for Molecular Diagnosis Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nucleic Acids for Molecular Diagnosis Market by Type
  1. 4.1 Nucleic Acids for Molecular Diagnosis Type Introduction
  2. 4.1.1 DNA Series
  3. 4.1.2 RNA Series
  4. 4.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Type
  5. 4.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Type (2021-2032)
  7. 4.2.3 Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Type (2021-2032)
5 Nucleic Acids for Molecular Diagnosis Market by Application
  1. 5.1 Nucleic Acids for Molecular Diagnosis Application Introduction
  2. 5.1.1 Early Cancer Screening
  3. 5.1.2 Genetic Diseases
  4. 5.1.3 Blood Screening
  5. 5.1.4 Genome Sequencing
  6. 5.1.5 Infectious Diseases
  7. 5.1.6 Other
  8. 5.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Application
  9. 5.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Application (2021-2032)
  11. 5.2.3 Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Application (2021-2032)
6 Nucleic Acids for Molecular Diagnosis Regional Value Analysis
  1. 6.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032)
  7. 6.3.2 North America Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032)
  10. 6.4.2 Europe Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032)
  16. 6.6.2 South America Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nucleic Acids for Molecular Diagnosis Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2025 VS 2032
7 Nucleic Acids for Molecular Diagnosis Country-level Value Analysis
  1. 7.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilent Technologies, Inc.
  2. 8.1.1 Agilent Technologies, Inc. Company Information
  3. 8.1.2 Agilent Technologies, Inc. Business Overview
  4. 8.1.3 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
  6. 8.1.5 Agilent Technologies, Inc. Recent Developments
  7. 8.2 Aji Bio-Pharma
  8. 8.2.1 Aji Bio-Pharma Company Information
  9. 8.2.2 Aji Bio-Pharma Business Overview
  10. 8.2.3 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Portfolio
  12. 8.2.5 Aji Bio-Pharma Recent Developments
  13. 8.3 Bio-synthesis Inc.
  14. 8.3.1 Bio-synthesis Inc. Company Information
  15. 8.3.2 Bio-synthesis Inc. Business Overview
  16. 8.3.3 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
  18. 8.3.5 Bio-synthesis Inc. Recent Developments
  19. 8.4 Danaher Corporation
  20. 8.4.1 Danaher Corporation Company Information
  21. 8.4.2 Danaher Corporation Business Overview
  22. 8.4.3 Danaher Corporation Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Portfolio
  24. 8.4.5 Danaher Corporation Recent Developments
  25. 8.5 Eurofins Scientific SE
  26. 8.5.1 Eurofins Scientific SE Company Information
  27. 8.5.2 Eurofins Scientific SE Business Overview
  28. 8.5.3 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Portfolio
  30. 8.5.5 Eurofins Scientific SE Recent Developments
  31. 8.6 Integrated DNA Technologies
  32. 8.6.1 Integrated DNA Technologies Company Information
  33. 8.6.2 Integrated DNA Technologies Business Overview
  34. 8.6.3 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
  36. 8.6.5 Integrated DNA Technologies Recent Developments
  37. 8.7 Kaneka Eurogentec S.A.
  38. 8.7.1 Kaneka Eurogentec S.A. Company Information
  39. 8.7.2 Kaneka Eurogentec S.A. Business Overview
  40. 8.7.3 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Portfolio
  42. 8.7.5 Kaneka Eurogentec S.A. Recent Developments
  43. 8.8 L.G.C Biosearch Technologies
  44. 8.8.1 L.G.C Biosearch Technologies Company Information
  45. 8.8.2 L.G.C Biosearch Technologies Business Overview
  46. 8.8.3 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  47. 8.8.4 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
  48. 8.8.5 L.G.C Biosearch Technologies Recent Developments
  49. 8.9 Merck KGaA
  50. 8.9.1 Merck KGaA Company Information
  51. 8.9.2 Merck KGaA Business Overview
  52. 8.9.3 Merck KGaA Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck KGaA Nucleic Acids for Molecular Diagnosis Product Portfolio
  54. 8.9.5 Merck KGaA Recent Developments
  55. 8.10 metabion
  56. 8.10.1 metabion Company Information
  57. 8.10.2 metabion Business Overview
  58. 8.10.3 metabion Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  59. 8.10.4 metabion Nucleic Acids for Molecular Diagnosis Product Portfolio
  60. 8.10.5 metabion Recent Developments
  61. 8.11 QIAGEN
  62. 8.11.1 QIAGEN Company Information
  63. 8.11.2 QIAGEN Business Overview
  64. 8.11.3 QIAGEN Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  65. 8.11.4 QIAGEN Nucleic Acids for Molecular Diagnosis Product Portfolio
  66. 8.11.5 QIAGEN Recent Developments
  67. 8.12 Thermo Fisher Scientific Inc.
  68. 8.12.1 Thermo Fisher Scientific Inc. Company Information
  69. 8.12.2 Thermo Fisher Scientific Inc. Business Overview
  70. 8.12.3 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
  72. 8.12.5 Thermo Fisher Scientific Inc. Recent Developments
  73. 8.13 Hongene
  74. 8.13.1 Hongene Company Information
  75. 8.13.2 Hongene Business Overview
  76. 8.13.3 Hongene Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hongene Nucleic Acids for Molecular Diagnosis Product Portfolio
  78. 8.13.5 Hongene Recent Developments
  79. 8.14 Synthgene
  80. 8.14.1 Synthgene Company Information
  81. 8.14.2 Synthgene Business Overview
  82. 8.14.3 Synthgene Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Synthgene Nucleic Acids for Molecular Diagnosis Product Portfolio
  84. 8.14.5 Synthgene Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst